Drug Detail

Information about Mekinist

Generic Name	Trametinib
IND	GSK1120212
Brand Name (US)	Mekinist
Manufacturer	GlaxoSmithKline
Drug Type
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	Melanoma, BRAF driven cancers
Overall Strategy
Strategy	Block related tumor signal paths
Drug Category	MEK inhibitor

Trametinib is a MEK1 and MEK2 inhibitor. It was approved by the FDA (USA) for use in BRAF mutated melanoma in January, 2014.
It is used as a single agent or in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
The recommended dosage regimens of MEKINIST are 2 mg orally once daily as a single agent or in combination with dabrafenib 150 mg orally twice daily. Take MEKINIST at least 1 hour before or at least 2 hours after a meal. See prescribing information.